Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of DN1406131 in Healthy Adults
NCT03641794Phase 1Unknown
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Sep 2018
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in solid tumor (advanced stage) comparing DN1406131 with Placebo (2 arms). Primary endpoints: Adverse events - type, incidence, severity at 28 days and Maximum Tolerated Dose at 14 days. Status: unknown.
02
Drugs
DN1406131
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03641794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641794.